Model selection is one of the highest-impact decisions in preclinical study design. The model shapes the quality of the data, the cost of the study, the ethical justification, and the strength of the regulatory narrative.
Start with the device question
The first step is to define what the model needs to show. A study focused on local tissue response may require different conditions than a study focused on deployment, fixation, healing, degradation, or long-term performance.
If the primary question is procedural handling, the model must allow a clinically meaningful procedure. If the question is biological response, the tissue environment and exposure duration may matter more.
Match the model to the intended use
The model should reflect the device’s anatomy, scale, procedure, exposure duration, and tissue interaction as closely as practical. For implants, that may include the implantation site, loading environment, vascularity, healing response, or ability to retrieve and evaluate the device. For delivery systems, it may include access route, operator handling, imaging, and deployment constraints.
Do not ignore model limitations
Every model has limitations. Some are anatomically convenient but biologically imperfect. Others may better represent the clinical setting but introduce higher cost, greater variability, or more complex logistics. These limitations are not automatically disqualifying, but they should be identified before the study begins.
A good study plan explains why the chosen model is appropriate and what the model cannot answer.
Consider feasibility early
A scientifically attractive model can still fail if it is not feasible. Teams should review facility experience, animal availability, surgical expertise, device compatibility, imaging access, pathology capabilities, recovery needs, and endpoint timing. Feasibility also includes whether the test article is ready and whether the procedure can be performed consistently enough to generate interpretable results.
Use pilot work when uncertainty is high
A pilot or feasibility study can be valuable when the model, procedure, device design, or endpoint is uncertain. It may reveal handling issues, endpoint timing problems, unexpected tissue response, or practical constraints before the team commits to a larger GLP or submission-supporting study.
The right model earns its place
The right model strengthens the entire development path. It improves data quality, supports clearer interpretation, reduces the risk of repeated studies, and helps ensure that animal use is scientifically justified.
Need guidance on preclinical strategy, biological evaluation, or study planning? Contact TEM Biomed to discuss your development program.
